Form 4: Beam Therapeutics Director John Maraganore Granted New Stock Options

Beam Therapeutics Inc. Director John Maraganore has been granted 33,662 stock options with an exercise price of $17.15, vesting over the next year.

Summary

• John Maraganore, a Director of Beam Therapeutics Inc. (BEAM), was granted 33,662 stock options.
• The transaction date for this grant was June 4, 2025.
• Each option has an exercise price of $17.15.
• The options are for Common Stock, with each option representing the right to buy one share.
• The options will vest in full on the earlier of the first anniversary of the grant date (June 4, 2026) or immediately prior to the date of the next year's annual meeting of stockholders.
• Vesting is contingent upon Mr. Maraganore's continued service to the board of directors.
• The options have an expiration date of June 4, 2035.
• Following this transaction, John Maraganore beneficially owns 33,662 derivative securities (stock options).

Sentiment

Score: 6

Explanation: The document reports a routine insider transaction (stock option grant) which is a standard part of director compensation. It's mildly positive as it aligns director interests with shareholders, but not significantly impactful on its own.

Positives

• The grant of stock options aligns the director's interests with those of shareholders, as the options gain value if the stock price increases.
• It represents a standard form of compensation for board members, indicating continued commitment and engagement from the director.

Future Outlook

The vesting schedule of the granted options implies an expectation of continued service from Director John Maraganore to the Beam Therapeutics board for at least the next year.

Industry Context

The granting of stock options to directors is a common practice in the biotechnology and pharmaceutical industries, serving as a key component of executive and board compensation packages. This practice aims to incentivize long-term value creation and align the interests of leadership with those of shareholders, which is particularly relevant in a sector characterized by long development cycles and significant R&D investment.

Related Party Transactions

• The grant of stock options to John Maraganore, a director, constitutes a related party transaction as it involves compensation from the company to an insider. This is a standard and disclosed form of compensation.

Stakeholder Impact

• Shareholders: The grant of options aligns the director's financial incentives with the company's stock performance, potentially benefiting shareholders through improved governance and strategic decisions aimed at increasing share value.

Next Steps

• Continued service of John Maraganore on the board of directors to fulfill vesting conditions.
• Vesting of the granted stock options on the specified date or prior to the next annual meeting.

Key Dates

Keywords

Beam Therapeutics, BEAM, Stock Option, Insider Transaction, Director Compensation, Equity Grant, Form 4, Biotechnology